Study of SGLT2 inhibitor effects on ketoacidosis risk
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 75 years old.
- Your body mass index (BMI) is between 21 and 45.
- Your average blood sugar (HbA1c) is between 7.0% and 11%.
- Your kidneys are working well (eGFR above 60).
- You take only certain diabetes medicines (like metformin, sulfonylureas, or stable doses of GLP-1 agonists or DPP-4 inhibitors). If you take an SGLT2 inhibitor, you must be willing to stop it for 2 months.
- You are not currently using insulin or thiazolidinediones (TZDs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This study tests different ways to monitor ketones (substances that can build up dangerously when your body lacks insulin) to lower the risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes who also take SGLT-2 inhibitors (a type of diabetes drug). You'll wear a small sensor and follow a meal plan with carbs.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.